Montelukast sodium : administration to children to control intermittent asthma
Loading...
Date
Authors
Gravett, Cornelia M.
Tintinger, Gregory Ronald
Theron, Annette J.
Anderson, Ronald
Feldman, Charles
Green, Robin J.
Journal Title
Journal ISSN
Volume Title
Publisher
Libertas Academica
Abstract
The prototype cysteinyl leukotriene receptor antagonist, montelukast, is generally considered to have a niche application in the chemotherapy of exercise-induced asthma. It has also been used as add-on therapy in patients whose asthma is poorly controlled with inhaled corticosteroid monotherapy, or with the combination of a long-acting β(2)-agonist and an inhaled corticosteroid.
Recently, however, montelukast has been reported to possess secondary anti-inflammatory properties, apparently unrelated to conventional antagonism of cysteinyl leukotriene receptors. These novel activities enable montelukast to target eosinophils, monocytes, and, in particular, the corticosteroid-insensitive neutrophil, suggesting that this agent may have a broader spectrum of anti-inflammatory
activities than originally thought. If so, montelukast is potentially useful in the chemotherapy of intermittent asthma because most exacerbations of this condition involve respiratory virus infection-triggered inflammatory mechanisms which, to a large extent, involve
airway epithelial cell/neutrophil interactions. The primary objective of this review is to evaluate the role of montelukast in the treatment
of intermittent asthma in children.
Description
Keywords
Airway epithelial cells, Corticosteroids, Inflammation, Neutrophils, Respiratory viruses, Virus-induced wheeze, Montelukast sodium
Sustainable Development Goals
Citation
Gravett, CM, Tintinger, GR, Theron, AJ, Anderson, R, Feldman, C & Green, R 2010, 'Montelukast sodium : administration to children to control intermittent asthma', Clinical Medicine Reviews in Therapeutics, vol. 2, pp. 1-10. [http://www.la-press.com/clinical-medicine-reviews-in-therapeutics-journal-j166]